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ABSTRACT 
Objectives: 
The purpose of this study was to compare the extent of p63 immunoreactivity in 
the malignant salivary gland neoplasms adenoid cystic carcinoma (ACC) and 
polymorphous low-grade adenocarcinoma (PLGA) and to compare it to the expression of 
this marker in the benign salivary gland tumor monomorphic adenoma (including 
canalicular adenoma and basal cell adenoma).  
p63, a selective histochemical marker of basal/stem cells of stratified epithelium 
and of myoepithelial cells, is a p53 homologue which plays an essential role in both 
morphogenesis of the epidermis and limb development. P63 immunoreactivity has been 
demonstrated in squamous cell and urothelial carcinomas, whereas it is generally absent 
in most non-squamous cell carcinomas.  
Little is known about the expression of p63 in head and neck salivary gland 
tumors have been published to date.   
Study Design: 
Formalin-fixed paraffin-embedded sections from 49 salivary gland neoplasms (17 
monomorphic adenomas, 17 PLGA and 15 ACC) accessioned between 1989 and 2002 by 
the Department of Pathology, Long Island Jewish Medical Center, New Hyde Park, NY, 
were stained with an anti-p63 monoclonal antibody. 
Results: 
Nuclear p63 reactivity was uniformly positive in PLGA (17/17, 100%). 
Positive reactivity was also identified in the majority of ACCs (13/15, 87%), 
primarily in the non-luminal myoepithelial-like cells surrounding the true luminal cells. 
The canalicular adenomas did not exhibit any p63 immunoreactivity. All of the 
basal cell adenomas of parotid origin stained strongly for p63, with staining localized to 
the peripheral tumor cells situated adjacent to the connective tissue stroma. None of the 
basal cell adenomas from the upper lip stained with p63. 
In the normal surrounding salivary gland tissue, p63 reactivity was identified only 
focally in the basal cells of striated ducts.  
Conclusions: 
We found that p63 is strongly expressed in basal cell adenomas of parotid origin, 
ACC and PLGA. Canalicular adenomas did not demonstrate any p63 staining, consistent 
with this tumor’s putative ductal luminal cell differentiation.  
Our results suggest that the neoplastic cells in PLGA may represent either 
myoepithelial cells or a population of p63-positive epithelial stem/reserve cells similar to 
the basal cells of stratified epithelium. 
P63 does not appear to be an ideal marker for distinguishing between ACC and 
PLGA in equivocal cases, or benign from malignant salivary gland neoplasms. 
INTRODUCTION 
P63, a selective histochemical marker of basal/stem cells of stratified epithelium 
and of myoepithelial cells1, is a p53 homologue which plays an essential role in both 
morphogenesis of the epidermis and limb development2. Recently3, it has been shown 
that p63 is required for p53-dependent apoptosis in response to DNA damage. 
Structurally, the p63 gene is located on chromosome 3q27-294 and encodes three 
isoforms, p63α, p63β and p63γ, which share a common amino-terminal end but differ at 
their carboxyl-terminal ends due to alternate mRNA splicings5. In addition, the gene for 
p63 contains a second promoter located upstream of exon 3, which gives rise to three 
amino-terminal deleted (p63ΔΝ) transcripts. The deleted amino-terminal region codes for 
a domain that is capable of trans-activating p53 target genes, including those involved in 
apoptosis. Consequently, p63ΔΝ isoforms lack p53-like activity. However, because they 
maintain their ability to compete with p53 for DNA target sites, p63ΔΝ isoforms appear 
to negatively regulate p53 activity6. These isoforms are the predominant type found in 
epithelial stem cells. 
The key role of p63 in embryogenesis has been demonstrated by knock out 
experiments in mice7. p63-deficient mice exhibit truncated forelimbs, absent hind limbs, 
absence of teeth, hair follicles and mammary glands. In p63-deficient mice, the oral 
epithelium consists of only a single layer of flattened epithelial cells7.  It appears that 
these deficiencies are caused by a perturbation of ectodermal-mesenchymal signaling, 
likely due to a lack of stem cells necessary to sustain epithelial morphogenesis and 
renewal8. In the absence of p63 expression, the basal cells undergo terminal 
differentiation, effectively running out of stem cells. It has been hypothesized that the 
preferential expression of the transactivation-deficient p63ΔΝ isoforms protects the basal 
epithelial cells from p53-induced apoptosis6. 
 
In humans, p63 gene mutations are involved in the pathogenesis of at least five 
autosomal dominantly inherited syndromes characterized by various combinations of 
limb deformities9,10. The most common of these is ectrodactily, ectodermal dysplasia and 
facial clefts syndrome (EEC), which closely resembles the phenotype seen in p63-
deficient homozygous mice5. 
 
At the cellular level, p63 is constitutively expressed in the basal cell nuclei of 
many normal stratified epithelial tissues6, including skin, squamous epithelium of the oral 
cavity, esophagus and cervix, prostatic acinar basal cells, esophageal mucosal gland 
ducts, and urothelium. P63 is strongly expressed in breast myoepithelial cells11 and is 
also expressed in normal thymus and in thymomas13. P63 expression is not found in the 
basal non-stratified epithelium of the stomach, colon or small intestine12, nor is it 
detected in normal mesenchymal or neural/neuroendocrine tissue13.  
Myofibroblasts are consistently negative for p63. This is in contrast to other 
myoepithelial markers such as calponin and smooth muscle actin, which can show 
variable myofibroblastic staining. 
Barbareschi et al11 identified a small subset of p63 positive, alpha-smooth muscle 
actin negative basal cells in the human breast, which may represent the breast somatic 
stem cell. 
 
A direct role for p63 in tumorogenesis has not been demonstrated to date, 
although amplification of the 3q27 region has been seen in a number of tumors, including 
squamous cell carcinoma4. This is suggestive of a putative role as an oncogene rather 
than as a tumor suppressor gene6. 
 
In neoplastic tissue, p63 immunoreactivity has been demonstrated in squamous 
cell and urothelial carcinomas14, whereas it is generally absent in most non-squamous cell 
carcinomas11. Adenocarcinomas reportedly do not express p6313.  
This loss of immunoreactivity in non-squamous cell malignant neoplasms has 
been exploited to aid in identifying microinvasion in cases of DCIS and LCIS11, and to 
differentiate benign prostatic tissue from adenocarcinoma14-15. In the case of poorly 
differentiated metastatic carcinomas, positive immunostaining for both p63 and CK5/6 is 
highly predictive of a primary tumor of squamous epithelial origin14. 
 
To date, no in depth studies on the expression of p63 in malignant head and neck 
salivary gland tumors have been published. Di Como et al13 reported positive p63 
reactivity in 4/4 benign mixed tumors of the parotid gland and 2/4 unspecified salivary 
gland carcinomas. In abstract form, Krane et al16 reported p63 positivity in a limited 
number of salivary gland neoplasms, including ACC, PLGA and basal cell adenoma.  
The purpose of this study was to compare the extent of p63 immunoreactivity in 
adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma and monomorphic 
adenoma. 
 
MATERIALS AND METHODS 
Formalin-fixed paraffin-embedded sections from 49 salivary gland neoplasms (17 
monomorphic adenomas, 17 PLGA and 15 ACC) accessioned between 1989 and 2002 
were retrieved from the files of the Department of Pathology, Long Island Jewish 
Medical Center. 
The H&E stained slides were independently reviewed by two experienced 
pathologists (RK, TB) and agreement was reached on all cases included in this study 
using accepted criteria17. 
Microwave heat-induced epitope retrieval (750 W microwave at medium power, 
30 minutes) was performed using the Trilogy™ system (Cell Marque, Hot Springs AK) 
as per the manufacturer’s directions and then treated with anti-human p63 monoclonal 
antibody that detects all isoforms (Ab-4, clones 4A4 and Y4A3; Neomarkers, Fremont 
CA) at a 1:50 dilution. 
The antibody-antigen complex was detected using an indirect biotin-avidin 
system as per the manufacturer’s instructions (Ventana Basic DAB Detection Kit™, 
Ventana Medical Systems, Tucson AZ). 
Fetal adrenal cortex was used as positive control. Normal salivary gland tissue 
was used as the negative control. When present, stratified squamous epithelium was used 
as an internal positive control. 
Immunoreactivity was independently assessed by all study participants. 
Agreement was reached on all 49 specimens examined. Immunoreactivity was considered 
positive if greater than 10% of the tumor cells stained and was graded as weak (10-25%), 
mild (26-50%), moderate (51-75%) and strong (76-100%).
RESULTS 
The ACC group, comprising 12 women and 3 men, had a median age of 65 years 
(range: 37-89 years). The tumor group included 8 lesions of minor salivary gland origin 
(4 palate, 3 soft tissue of the neck, 1 maxillary sinus) and 7 lesions of major gland origin 
(5 parotid, 2 submandibular gland). The histological subtypes include 4 cribriform, 3 
tubular and 8 solid patterns. 
The median age of the PLGA group was 67 years (range: 38-73 years) and 
consisted of 13 female patients and 4 male patients. All tumors arose from minor salivary 
gland tissue, primarily palate (8) and buccal mucosa (4), except for one of parotid origin. 
The monomorphic adenoma group, comprising 14 women and 3 men, had a 
median age of 66 years (range: 41-97). The tumors were located in the upper lip (9), 
parotid (4), buccal mucosa (3), and hard palate (1) and comprised 6 canalicular adenomas 
and 11 basal cell adenomas. 
 
P63 nuclear staining (Table 1) was uniformly positive in all PLGAs (17/17, 
100%), with at least 25% of the tumor cells being positive (Figure 1).  
Positive reactivity was also identified in the majority of ACCs (13/15, 87%; 
Figure 2). Staining was located primarily in the non-luminal myoepithelial-like cells 
surrounding the true luminal cells. The small polygonal luminal cells characterized by 
pale eosiniphilic cytoplasm failed to stain for p63. The two cases of ACC with no 
immunoreactivity and the single case with weak p63 immunoreactivity were 
predominantly of the solid variant. However, 5 of 8 solid ACCs stained strongly. 
The monomorphic adenomas variably expressed the p63 antigen (6/17, 35%). 
Subdividing the monomorphic adenomas (Table 2) demonstrated no staining in the 
canalicular adeoma subtype (Figure 3a) and variable staining in the basal cell adenomas 
(Figure 3b). All basal cell adenomas of parotid origin stained strongly positive for p63. 
Staining was localized to the peripheral tumor cells located adjacent to the connective 
tissue stroma. None of the basal cell adenomas from the upper lip stained for p63. 
In the normal surrounding salivary gland tissue, immunoreactivity was focally 
detected in the basal cells of striated ducts. 
 
 ADENOID 
CYSTIC 
CARCINOMA 
POLYMORPHOUS 
LOW GRADE 
ADENOCARCINOMA 
MONOMORPHIC 
ADENOMA 
 
    
Total number of 
samples 
15 
 
17 17 
Negative staining 
 
2  
(Note 1) 
0 11 
Weak staining 
(10-25% of cells) 
1 
(Note 2) 
0 0 
Mild staining 
(26-50%) 
0 
 
4 1 
Moderate staining 
(51-75%) 
1 
 
3 1 
Strong staining  
(76-100%) 
11 
 
10 4 
%  samples with 
positive staining 
87% 100% 35% 
 
 
Table 1:  Summary of p63 staining results 
 
Note 1: Both lesions with no staining were solid variants of ACC 
Note 2: This lesion was mostly solid variant of ACC 
 
 
 
 Canalicular Adenomas (N=6) 
 
Basal Cell Adenomas (N=11) 
Origin Parotid 
 
Upper Lip Other 
Minor 
Gland 
Parotid Upper Lip Other  
Minor 
Gland 
       
Negative staining 
 
- 5 1 - 4 1 
Weak staining 
(10-25% of cells) 
- - - - - - 
Mild staining 
(26-50%) 
- - - - - 11 
Moderate staining 
(51-75%) 
- - - - - 1 
Strong staining  
(76-100%) 
- - - 4 - - 
%  samples with 
positive staining 
0% 66% 
 
Table 2:  Summary of p63 staining results by subtype of 
monomorphic adenoma (canalicular adenoma versus basal cell 
adenoma) and by site of origin 
 
Note 1: This lesion had features of both canalicular adenoma and basal cell adenoma. The 
basal cell adenoma area stained for p63, whereas the canalicular adenoma area did not. 
 
DISCUSSION 
 
The participation of myoepithelial cells in certain salivary gland neoplasms such 
as adenoid cystic carcinoma is generally accepted17. Our results are in agreement with 
these findings. We found strong positive p63 nuclear staining in 12 of 15 ACCs 
examined. The two cases of ACC with no immunoreactivity and the single case with 
weak p63 immunoreactivity were predominantly of the solid variant. Nevertheless, most 
solid ACCs examined showed strong p63 immunoreactivity,.  
 
Polymorphous low-grade adenocarcinoma appears to show little evidence of 
myoepithelial differentiation, although this view has been challenged18. While Jones et 
al18 reported focal alpha-smooth muscle actin in 5 of 6 PLGAs examined, Regezi et al19 
reported positive immunstaining for S100 and vimentin but only weak staining for 
muscle-specific actin in 2 of 15 PLGAs.  Prasad et al20 compared the immunoreactivity of 
13 cases of ACC, 26 cases of PLGA and 17 cases of canalicular adenomas stained with 
the smooth muscle-specific monoclonal antibodies α-smooth muscle actin, smooth 
muscle myosin heavy chain and calponin and demonstrated that the ACCs consistently 
stained positive for myoepithelial markers in ACCs and lacked staining in PLGAs and 
canalicular adenomas. They concluded that there was no evidence of myoepithelial 
differentiation in PLGA.  The results of Araujo et al21, in which only 3 of 28 PLGAs 
demonstrated mild muscle specific actin immunoreactivity, appear to confirm this 
interpretation. No myoepithelial-like cells were identified in five cases examined by 
transmission electron microscopy21.  
Our results suggest that the neoplastic cells in PLGA may represent either 
myoepithelial cells or a population of p63-positive epithelial stem/reserve cells similar to 
the basal cells of stratified epithelium. In light of previously published 
immunohistochemical and ultrastructural studies suggesting the absence of myoepithelal 
participation in the histogenesis of PLGA, our findings could be interpreted as suggesting 
that the neoplastic cells in PLGA may represent a population of p63-positive epithelial 
stem/reserve cells similar to the basal cells of stratified epithelium. However, in the 
absence of double-staining experiments on the same specimens using both p63 and 
cytoplasmic markers of myoepithelial cell origin (e.g. calponin and smooth muscle actin), 
the involvement of myoepithelial cells in the histogenesis of PLGA cannot be ruled out. 
 
We were unable to demonstrate any p63 staining in the canalicular adenomas. 
This is in agreement with previous findings that have demonstrated an absence of 
myopeithelial differentiation in canalicular adenomas both by immunohistochemical20 
and ultrastructural studies22, and is consistent with this tumor’s putative ductal luminal 
cell differentiation23.  
Variable p63 staining was identified in the basal cell adenomas. All of the basal 
cell adenomas of parotid origin stained strongly for p63, with staining localized to the 
peripheral tumor cells situated adjacent to the connective tissue stroma. Zarbo et al23 
reported similar staining patterns using the myoepithelial markers troponin, smooth 
muscle myosin heavy chain and α-smooth muscle actin. None of the basal cell adenomas 
from the upper lip in our study stained for p63. This is not incompatible with the 
ultrastructural and immunohistochemical studies that have demonstrated relative 
differences in the extent of ductal luminal, myoepithelial and basal cell differentiation 
between different basal cell adenomas17, which may in part be a function of the site of 
origin of the neoplastic tissue.  
 
 CONCLUSIONS 
Nuclear p63 reactivity was uniformly positive in PLGA. Since p63 is a selective 
histochemical marker of both basal/stem cells of stratified epithelium and of 
myoepithelial cells,  our results suggest that the neoplastic cells in PLGA may represent 
either myoepithelial cells or a population of p63-positive epithelial stem/reserve cells 
similar to the basal cells of stratified epithelium. 
Positive p63 reactivity was also identified in the majority of ACCs.  
Monomorphic adenomas variably expressed the p63 antigen, with the canalicular 
adenomas demonstrating no staining and the basal cell adenomas of parotid gland origin 
exhibiting strong staining. In the normal surrounding salivary gland tissue, p63 reactivity 
was identified only focally in basal cells of striated ducts. 
In summary, we find that p63 does not appear to be an ideal marker for 
distinguishing between ACC and PLGA in equivocal cases, or benign from malignant 
salivary gland neoplasms.  
 
 
 
Figure 1: Polymorphous low-grade adenocarcinoma adjacent to overlying 
normal surface epithelium. (A) Hematoxylin and eosin stain, and (B) p63 
demonstrating strong nuclear staining in the neoplastic cells. Note the 
positive p63 staining in the basal layer of normal stratified squamous 
epithelium (original magnification 100x). 
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Figure 2: Adenoid cystic carcinoma. (A) Hematoxylin and eosin stain, and (B) p63. 
Note that the polygonal luminal cells (arrow) do not stain, whereas  the surrounding 
non-luminal myoepithelial/basal reserve cells show strong nuclear p63 
immunoreactivity (original magnification 200x). 
 
 
 
 
 Figure 3a: Monomorphic adenoma, canalicular adenoma subtype. (A) Hematoxylin 
and eosin stain, and (B) p63. Note the positive p63 staining in the normal basal 
epithelium and the lack of nuclear staining in the neoplastic cells (original 
magnification 100x)  
 
 
 
 
 
 
 
 
 
 
 
 Figure 3b: Monomorphic adenoma, tubulo-trabecular basal cell adenoma subtype. 
(A) Hematoxylin and eosin stain, and (B) p63 demonstrating nuclear staining in the 
neoplastic cells. Note that the p63 staining is primarily localized to the peripheral 
tumor cells adjacent to the connective tissue stroma (original magnification 100x). 
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